Ingenia Therapeutics, a Watertown, Massachusetts-based biotechnology company whose lead ophthalmology antibody is being developed by Merck, received approval from the Korea Exchange (KRX) to proceed with an initial public offering. The IPO represents an unusual move for a US-headquartered biotech to access Korean capital markets, however Ingenia also has Korean-based operations and a local subsidiary. Offering size, price range, and gross proceeds had not been disclosed at the time of the announcement.
Company background
Ingenia operates two proprietary antibody engineering platforms — TIE-body and LCIDEC — centered on direct activation of the TIE2 receptor, a mechanism the company states stabilizes endothelial cells and restores vascular barrier function independent of Ang1/Ang2 ligand signaling. Its lead asset, IGT-427, was out-licensed to EyeBio in 2022 and is now designated MK-8748 (Tiespectus) following Merck's acquisition of EyeBio in 2024. Merck is advancing MK-8748 into Phase III development across wet age-related macular degeneration and diabetic macular edema in 2026. A Phase I/2a trial of MK-8748 in branch retinal vein occlusion patients produced a 16.7-letter gain in best-corrected visual acuity from baseline after three monthly doses, the company stated, providing the basis for pivotal advancement.
Ingenia's second clinical asset, IGT-303, targets glomerular and tubular endothelial restoration in chronic kidney disease and diabetic kidney disease and is progressing through a Phase I/IIa trial, with first-in-human dosing completed in November 2025 and data expected in the second half of 2026. No FDA regulatory designations were disclosed for either asset. The company has operations in South Korea and Australia in addition to its Massachusetts headquarters, and the KRX listing reflects its stated Korean operational roots. The filing did not provide a detailed breakdown of use of proceeds beyond general platform and pipeline acceleration.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Spot something wrong? Report an issue with this article